Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 7, 2016; 22(37): 8398-8405
Published online Oct 7, 2016. doi: 10.3748/wjg.v22.i37.8398
Published online Oct 7, 2016. doi: 10.3748/wjg.v22.i37.8398
Table 1 Patient demographics
| Characteristic | |
| Gender (n) | |
| Men | 46 |
| Women | 31 |
| Age (yr) | 46 ± 11 (19-67) |
| BMI (kg/m2) | 32.1 ± 4.9 (27.7-51.4) |
| HbA1c (%) | 8.3 ± 1.6 (5.5-13.3) |
| Mean T2DM duration(yr) | 7 ± 5 (1-25) |
| Concomitant disorder (n) | |
| Hyperlipidemia | 38 |
| Fatty liver | 31 |
| Hypertension | 29 |
| Follow-upduration (n) | |
| 6 mo | 77 |
| 12 mo | 56 |
| 24 mo | 33 |
| 36 mo | 6 |
Table 2 Postoperative complications in laparoscopic Roux-en-Y gastric bypass patients
| Complications | n (%) |
| Early complications (< 30 p-o d) | |
| JJA bleeding | 1 (1.3) |
| Late complications (> 30 p-o d) | |
| GJA stenosis | 1 (1.3) |
| Intestinal obstruction | 6 (7.8) |
| Iron deficiency anemia | 2 (2.6) |
| Acute pancreatitis | 1 (1.3) |
| Upper gastrointestinal hemorrhage | 1 (1.3) |
| Gallstones | 5 (7.6) |
| Total | 17 (23.2) |
Table 3 Determination of body mass index and glycosylated hemoglobin before and after laparoscopic Roux-en-Y gastric bypass surgery
| Follow-up | Pre-op. | 3 mo Post-op. | 6 mo Post-op. | 12 mo Post-op. | 24 mo Post-op. | F value | P value | |
| 12 mo (n = 56) | BMI (kg/m2) | 32.3 ± 5.0 | 26.6 ± 4.5 | 25.3 ± 4.1 | 24.9 ± 4.0 | / | 33.738 | 0.000 |
| HbA1c (%) | 8.1 ± 1.6 | 6.2 ± 1.0 | 5.7 ± 0.6 | 6.1 ± 1.1 | / | 47.506 | 0.000 | |
| 24 mo (n = 33) | BMI (kg/m2) | 31.2 ± 3.5 | 25.8 ± 3.5 | 24.3 ± 3.1 | 24.0 ± 2.9 | 24.4 ± 2.9 | 29.550 | 0.000 |
| HbA1c (%) | 8.5 ± 1.7 | 6.2 ± 0.9 | 5.5 ± 0.7 | 5.7 ± 0.6 | 6.2 ± 1.0 | 41.135 | 0.000 | |
Table 4 Diabetes mellitus parameters in patients combined with/without anti-diabetemedications after Laparoscopic Roux-en-Y gastric bypass surgery n (%)
| HbA1c level | Preop (n = 77) | 3 mo postop. (n = 77) | 6 mo postop. (n = 77) | 12 mo postop. (n = 56) | 24 mo postop. (n = 33) |
| Without anti-diabetes | 6 (7.8) | 54 (70.1) | 56 (72.7) | 47 (83.9) | 26 (78.8) |
| medications | |||||
| HbA1c < 7.0% | 3 (3.9) | 51 (66.2) | 54 (70.1) | 45 (80.4) | 22 (66.7) |
| HbA1c ≤ 6.5% | 1 (1.3) | 47 (61.0) | 49 (63.6) | 42 (75) | 21 (63.6) |
| HbA1c ≤ 6.0% | 0 (0) | 34 (44.2) | 37 (48.1) | 36 (64.3) | 15 (45.5) |
| With anti-diabetes | 71 (92.2) | 23 (29.9) | 21 (27.3) | 9 (16.1) | 7 (21.2) |
| medications | |||||
| HbA1c < 7.0% | 15 (19.5) | 13 (16.9) | 10 (13.0) | 5 (8.9) | 5 (15.1) |
| HbA1c ≤ 6.5% | 9 (11.7) | 9 (11.7) | 8 (10.4) | 3 (5.4) | 4 (12.1) |
| HbA1c ≤ 6.0% | 4 (5.2) | 3 (3.9) | 3 (3.9) | 3 (5.4) | 1 (3.0) |
Table 5 Patients with improved diabetes mellitus after laparoscopic Roux-en-Y gastric bypass n (%)
| HbA1c level | Preop | 3 mo postop. (n = 77) | 6 mo postop. (n = 77) | 12 mo postop. (n = 56) | 24 mo postop. (n = 33) | P value | |||
| No. of patients | (n = 77) | 3 mo postop vs Preop | 6 mo postop vs Preop | 12 mo postop vs Preop | 24 mo postop vs Preop | ||||
| HbA1c < 7.0% | 18 (23.4) | 64 (83.1) | 64 (83.1) | 50 (89.3) | 27 (81.8) | 0.000 | 0.000 | 0.000 | 0.000 |
| HbA1c ≤ 6.5% | 10 (13.0) | 56 (72.7) | 57 (74.0) | 45 (80.4) | 25 (75.8) | 0.000 | 0.000 | 0.000 | 0.000 |
| HbA1c ≤ 6.0% | 4 (5.2) | 37 (48.1) | 40 (51.9) | 39 (69.6) | 16 (48.5) | 0.000 | 0.000 | 0.000 | 0.000 |
Table 6 Patients with concomitant disorders before and after 12 mo of laparoscopic Roux-en-Y gastric bypass surgery (n = 56)
| Concomitant disorders (n) | Pre-surgery | 12 mo post-surgery | P value |
| Dyslipidemia | 38 | 7 | 0.000 |
| Fatty liver | 31 | 4 | 0.000 |
| Hypertension | 29 | 8 | 0.000 |
- Citation: Bai RX, Yan WM, Li YG, Xu J, Zhong ZQ, Yan M. Application of side-to-side anastomosis of the lesser curvature of stomach and jejunum in gastric bypass. World J Gastroenterol 2016; 22(37): 8398-8405
- URL: https://www.wjgnet.com/1007-9327/full/v22/i37/8398.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i37.8398